Drug intelligence / Profile preview

bevacizumab + capecitabine + everolimus

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of bevacizumab (an anti-VEGF monoclonal antibody), capecitabine (a prodrug that converts to fluorouracil in tumor cells), and everolimus (an mTOR inhibitor). This regimen targets multiple pathways in cancer cells, with preclinical data suggesting that combined VEGF and mTOR inhibition provides greater anti-angiogenic and anti-tumor activity than either approach alone. The combination has been studied in clinical trials for metastatic colorectal cancer and advanced breast cancer.

Targets

Mechanistic target of rapamycin complex 1TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + capecitabine + everolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + capecitabine + everolimus.

Explore the full profile